Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men

AIDS

Volumn 18, Issue 14, 2004, Pages 1958-1961

  Ghosn, Jade ^a,g   Chaix, Marie Laure ^a   Peytavin, Gilles ^d   Rey, Elisabeth ^e   Bresson, Jean Louis ^b   Goujard, Cécile ^f   Katlama, Christine ^g   Viard, Jean Paul ^c   Tréluyer, Jean Marc ^e   Rouzioux, Christine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Centre d'investigations cliniques HÔpital européen Georges Pompidou   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICHAT HOSPITAL   (France)

^e HÔPITAL SAINT VINCENT DE PAUL   (France)

^f BICÊTRE HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD TESTIS BARRIER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; MALE GENITAL SYSTEM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SPERM; TREATMENT FAILURE; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; BLOOD-TESTIS BARRIER; GENITALIA, MALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; PEPTIDE FRAGMENTS; PHOSPHONIC ACIDS;

EID: 4744357409     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409240-00014     Document Type: Article

References (24)

1. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and in semen of pre-treated HIV-infected men. AIDS 2004; 18:447-457.
2. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826.
3. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001; 77:4-11.
4. Aamnoutse RE, Verweij-van Wissen CP, Underberg WJ, Kleinnijenhuis J, Hekster YA, Burger DM. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. J Chromatogr B Biomed Sci Appl 2001; 764:363-384.
5. Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003; 25:340-346.
6. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy) propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42:687-690.
7. Lawless MK, Hopkins S, Anwer MK. Quantitation of a 36-amino-acid peptide inhibitor of HIV-1 membrane fusion in animal and human plasma using high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 707:213-217.
8. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
9. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
10. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18:685-693.
11. Flaherty JF, Kearney BP, Wolf JJ, Sayre JR. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. In: 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001 [Abstract 336].
12. van Praag RM, van Heeswijk RP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001; 33: e91-e92.
13. van Praag RME, Weverling GJ, Portegies P, Juriaans S, Zhour X-J, Turner-Foisy ML, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14:1187-1194.
14. Sankatsing SU, Droste J, Burger D, van Praag RME, Juriaans S, Lange JM, Prins JM. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS 2002; 16:1698-1700.
15. Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 2001; 48:351-354.
16. Agenerase (package insert). Glaxo-SmithKline, Research Triangle Park, NC, USA; 2001.
17. Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Wire MB, Fiscus SA, Kashuba AD. Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis 2002; 35:760-762.
18. Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group Study 850). J Infect Dis 2002; 186:198-204.
19. Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, et al. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis 2002; 186:1339-1343.
20. Taylor S, Reynolds H, Sabin CA, Caroline A, Drake SM, White DJ, et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 2001; 15:2051-2053.
21. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
22. Gathe JC, Washungton M, Mayberry C, Piot D. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV+ ARV naive patients: interim analysis of subjects completing at least 24 weeks of a 48-week study. In: 43rd Annual ICAAC Conference. Chicago, USA, 14-17 September 2003 [Abstract H8453].
23. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker U, Vernazza PL. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-959.
24. Little SJ, Koelsch KK, Ignacio CC, et al. Transmission, selection and persistence of drug-resistant virus. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, USA, 8-11 February 2004 [Abstract 36LB].